Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
(Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides.
- (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides.
- She replaces Jakob Lindberg, who has been the CEO since November 15, 2021.
- Lindberg assumes his previous position as Chief Scientific Officer.
- "I am also very grateful that Jakob Lindberg will continue his dedicated scientific engagement in Oncopeptides, in his capacity as Chief Scientific Officer."